- Details
- James Borin speaks about the revolution and the evolution of percutaneous renal surgery. The evolution of the technique is now using ultrasound guidance and smaller scopes, mini-percs with endoscopic guidance. Dr. Borin answers the following questions during his presentation: who can have a supine PCNL? What is it?, and When should it be done ambulatory? He also describes what he calls a hybrid pr...
|
- Details
- Ashley Baker presents on percutaneous renal biopsy in the ambulatory surgery center. Dr. Baker presents in favor of urologists being involved and of the safety of the procedure being performed in the ambulatory surgery center. Biographies: Ashley Baker, MD, Urology Specialist, Shreveport, Louisiana, USA. Moderator: Evan R. Goldfischer, MD, MBA Related Content: Biopsy of the Small Renal Mass - Stil...
|
- Details
- Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...
|
- Details
- In this discussion with Charles Ryan, MD, Christopher Logothetis discusses his perspective on the direction and growth of the prostate cancer foundation (PCF) and what it has meant to the field of urology. Dr. Logothetis reviews his involvement in the foundation, as well as his thoughts on the developments of treatments and platforms in prostate cancer focusing specifically on differences between...
|
- Details
- In this episode of Kidney Cancer Today, Jaime Landman helps Monty Pal dissect some of the biggest issues on active surveillance for renal cell carcinoma. The following questions were discussed. Who is the right patient for active surveillance? Can a T1b patient be a candidate for active surveillance? What are the best clinical practices post five years after resection in the surveillance setting?...
|
- Details
- Howard Soule discusses highlights and his takeaways from the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Soule highlights the importance of coming to these conferences to understand where the gaps are in the treatment landscape and the benefit of these global conferences for clinicians from resource-limited countries. They continue on to discuss imaging, PSMA, and the VISION tr...
|
- Details
- Christopher Logothetis and Charles Ryan review key takeaways from Christopher Logothetis's Advanced Prostate Cancer Consensus Conference (APCCC 2019) presentation on Ethnicity and Prognosis of Prostate Cancer and the importance in understanding the differences in outcomes of individuals with the disease based on race and ethnicity. In his work Dr. Logothetis prepared for APCCC 2019, he presses the...
|
- Details
- Deborah Mukherji sits down with Carmel Pezaro at the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to share her perspective on how prostate cancer care in the Middle East, specifically Lebanon, compares to the rest of the globe. They discuss the impact and the potential of genomic testing and the use of novel imaging, such as PSMA PET/CT relevant to work in the Middle East and in Leba...
|
- Details
- Ana Aparicio discusses her work with aggressive variant prostate cancer and her group’s research using immunohistochemistry results and genomic analysis to identify patients with a specific molecular signature. The research concludes that this molecular signature appears to identify the people that benefit from the addition of carboplatin to cabazitaxel chemotherapy. People that have the signature...
|
- Details
- Matt Rettig discusses POPCaP and his work involving the health of veterans with prostate cancer and ongoing clinical trials going on exclusively within the Veterans Health Administration (VA) system. The Precision Oncology Program for Cancer of the Prostate (POPCaP), a partnership between the VA and the Prostate Cancer Foundation (PCF) to create a system of excellence for prostate cancer in VA is...
|
